Volume 14 Issue 4 - International Pharmaceutical Industry

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Volume 14 Issue 4

Understanding Compliance: Moving from Cost to Value

Throughout the life sciences sector, the key trends of globalisation and digitalisation are providing new opportunities for growth and innovation. However, within de...

13 January 2023 Volume 14 Issue 4 accurately | compliance

Continue Reading →

Volume 14 Issue 4

EU CTR: Final Countdown, What You Need to Know

The end of the transition period is imminent. How can clinical trial sponsors and CROs ease the transition to CTIS? Soon, the one-year transition period of the EU...

13 January 2023 Volume 14 Issue 4 application | approval

Continue Reading →

Volume 14 Issue 4

Brexit – Impact, Challenges, and Solutions for The Pharmaceutical Industry

Brexit has provided several challenges to the pharmaceutical industry that required robust actions and swift resolution in order to remain in compliance following th...

13 January 2023 Volume 14 Issue 4 approval | Brexit

Continue Reading →

Volume 14 Issue 4

Bad Medicine: Lessons from an Enduring Alliance between Big Pharma and Global Policing

The challenges of tackling international crime with national law enforcement are legion. John Binns, a partner in the Financial Crime team at BCL Solicitors consider...

13 January 2023 Volume 14 Issue 4 consumers | enforcement

Continue Reading →

Volume 14 Issue 4

Driving a Vision for a Data-driven Regulatory Ecosystem

A data-driven Regulatory ecosystem has huge potential, beyond the opportunity for operational improvement. However, Regulatory and product teams will need updated da...

13 January 2023 Volume 14 Issue 4 opportunity | potential

Continue Reading →

Volume 14 Issue 4

Regulatory and Developmental Complexities Around Demonstrating Bioequivalence for a Topical Generic Product

Increasing Patient Access to HighQuality Topical Products The topical dermatology market, although niche, was estimated to be valued at approximately $20.4 billio...

13 January 2023 Volume 14 Issue 4 dermatology | topical

Continue Reading →

Volume 14 Issue 4

Opportunities for the IPO of Psychedelics Companies (or, How to Change Investors’ Minds)

If anyone had suggested only a few years ago that it is a realistic proposition to float a psychedelics company on any of the London markets, that suggestion would l...

13 January 2023 Volume 14 Issue 4

Continue Reading →

Volume 14 Issue 4

Technical Advancements in Proteomics Streamline High-throughput Workflows

Over the last two decades, significant advances in technology and new methodologies have made proteomics an extremely powerful tool for protein scientists, biologist...

13 January 2023 Volume 14 Issue 4

Continue Reading →

Volume 14 Issue 4

Pre-existing Immunogenicity: How Will Cell and Gene Therapies Change Our Testing Approach?

When bringing a therapeutic to market, determining its potential to elicit an immune response and understanding the molecular and cellular interactions involved is e...

13 January 2023 Volume 14 Issue 4

Continue Reading →

Volume 14 Issue 4

Strategies to Reduce Cold Chain Burden in Biopharmaceuticals

The availability of a wide range of therapeutic biologics has revolutionised modern medicine. Whilst the majority of pharmaceutical drug products remain conventional...

13 January 2023 Volume 14 Issue 4

Continue Reading →